Erlotinib, in combination with bevacizumab for the maintenance treatment of non-squamous advanced or metastatic non-small-cell lung cancer after previous platinum-containing chemotherapy
Status Suspended
Decision Selected
Process TA
Referral date 01 November 2008
Topic area
  • Cancer
  • Respiratory

Provisional Schedule

Closing date for invited submissions / evidence submission: TBC
1st appraisal committee meeting: TBC

Project Team

Communications manager: TBC
Executive Lead: TBC
Project manager: TBC
Technical Lead: TBC


Key events during the development of the guidance:

Date Update
30 July 2010

The manufacturer oferlotinib has advised us that regulatory approval for this technology is not being sought. The Institute has therefore decided to suspend this appraisal from its current work programme.

As this topic has been referred to the Institute we will continue to monitor any development and will update interested parties if the situation changes. If you have any comments or concerns please do not hesitate to contact the Project Manager for this appraisal, Cathryn Hall (020 7045 2240 or email: (

13 August Please note that following on from advice received from the manufacturer, this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during early August 2010. The deadline for submissions is expectedin approximately early October 2010.

For further information on our processes and methods, please see our CHTE processes and methods manual